Hello traders!

US markets turned higher tonight, with the Dow Jones Industrial Average last up 33.17 points at 12,449.77. The S&P500 was up 3.72 at 1,415.83 and the Nasdaq Composite ahead 16.43 at 2,451.

See you in the morning with the latest.....

G.

Good morning traders!

In Asia today, the Hang Seng ended the morning up 33.04 points at 19,601.38, while the Nikkei closed down 104.23 points at 16,838.18

New York Mercantile Exchange's main oil contract, light sweet crude for delivery in February, was down 69 cents at $53.33 from $54.02 in late trading in the US overnight.

Happy trading!

G.

Morning all.

Good morning all

AP. 9.75 - 10p +0.25p
A positive trading statement to look forward, as share is on a flat bottom of a 2 year chart

Thursday, 11th January 2007; 07.00 GMT London UK, and Dublin Ireland
Alltracel Pharmaceuticals plc
Q4 Trading Update
-- Trading profitability in line with analysts expectations --
-- Significant technological and commercial progress in NanopeuticsTM
subsidiary --
-- Nanopeutics entry into the global consumer woundcare, military and the global
blood filtration markets --
-- Final stage negotiations with a North American based CVH specialist to enter
the global nutrition market with a range of patented CVH functional food and
bio-active technologies --

Alltracel Pharmaceuticals Plc., ("Alltracel", or "the Company"), (AIM:AP.L), the
Medical Technology Company focussed on the Woundcare, Oralcare and
Cardiovascular Health markets, today announces that following the commencement
of first licence revenue in quarter four, analysis of initial consolidated
numbers indicate that full year 2006 numbers will be in line with analysts
profitability expectations.

Formal full year preliminary results are scheduled for release in early April
2007.

Highlights of the quarter include:

* Nanopeutics, the specialist subsidiary dedicated to the commercialisation
of NanospiderTM technology for the global woundcare markets, agrees a
license bearing exclusive nanotechnology development partnership with a
global leader in professional woundcare. The concept development project is
ahead of agreed schedule and the successful conclusion to the development
work will lead to an exclusive global royalty bearing licence and supply
agreement for NanospiderTM based technology and specialist products.

* Nanopeutics is currently finalizing negotiations on similar exclusive
concept development agreements with existing companies in a number of other
woundcare and related markets; specifically the global consumer woundcare,
the military and the global blood filtration markets. Separate
announcements are expected later this quarter.

* Following last quarters preclinical trials confirming wound and dermal
healing properties in a number of finalised product delivery systems
Alltracel are now in late stage negotiations with a specialist
anti-microbial supplier for the in-licencing of a novel anti-microbial
technology for exclusive commercialization rights for the global woundcare
markets: consumer, professional and military for textile, non-textile and
nanofibre applications.

* Following successful combination trials earlier this year and last
quarter's successful development of a highly soluble derivative of
Alltracel's patented cardiovascular health benefiting bioactive; subsequent
commercialisation negotiations are concluding with one of the combination
trial partners, a North American based CVH specialist, for the
establishment of a technology and business development alliance to enter
the global nutrition market with a range of patented CVH functional food
and bio-active technologies. A separate statement is expected shortly.

* Oralcare- continued strong oral care trade performance with business wins
in all major markets

Alltracel CEO Tony Richardson commented:

"We are pleased at the significant progress this quarter both in terms of
financial performance, technology breakthroughs and significant commercial
developments. Subject to final confirmation and audit we remain comfortable with
analysts' expectations of the business reaching full year profitability for the
year 2006.

Our oral care business continues to perform strongly and following the cessation
of our exploratory discussions last month concerning the potential disposal of
this division, we have progressed plans to grow this business via further
investment and potential M&A activity.

This quarter saw our first licence revenue and we are confident of a continued
growth in sustainable profitable revenue as we transition the business to more
of a licence and technology transfer business model rather than one focussed on
product revenue alone."

AP. chart

NCS
continues to go higher (BREAKOUT) as is aproaching time of the placing being done, EGM on Monday

BREAKOUT

Midday Market Roundup

        LUNCH TIME FUN

NCS 3.20 -3.40p +0.80p

Is going places today



Pasting This Chart To The Bulletin Board
To include this chart in a message posted to the bulletin board, copy and paste the code below, then include it in the text of your post.

If you are having any difficulty, please email us for help.

End-of-day Market Roundup

        JOKE OF THE DAY

An Englishman, a Scotsman and an Irishman apply to join the SAS.
In the recruiting interview, they are each asked
if they have a relative with them.

The Englishman has his mother with him, the Jock his wife
and the Irishman his Grandmother.

As a demonstration of absolute loyalty to the regiment,
each man is given a revolver and asked to go out
to the waiting room and shoot the relative.

The Englishman and Scotsman go out in turn, but return in shame,
unable to pull the trigger.

The Irishman goes out and a melee ensues, chairs and tables crashing
to the ground, grunts and screams issue forth....eventually silence
falls and the Irishman crashes back into the interview room....."

This gun wasn't loaded," he exclaims, "I had to strangle the bitch!"